|

Tunlametinib Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Tianjin Medical University Second Hospital1
  • Shanghai Kechow Pharma, Inc.1
  • Fudan University1

Indications

  • Cancer3
  • Advanced PDTC or ATC With NRAS Mutation1
  • Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation1
  • Solid Cancers1
  • Melanoma1

Other3 trials

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase 3
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.